煙肼酰胺
 | |
| 臨床資料 | |
|---|---|
| AHFS/Drugs.com | 國際藥品名稱 |
| 給藥途徑 | Oral |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 | |
| 識別資訊 | |
| |
| CAS號 | 51-12-7  |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.073 |
| 化學資訊 | |
| 化學式 | C16H18N4O2 |
| 摩爾質量 | 298.35 g·mol−1 |
| 3D模型（JSmol） | |
| |
| |
煙肼酰胺（英語：Nialamide，商品名有Niamid、Niamide、Nuredal、Surgex等）是一種含氮有機化合物，化學式C16H18N4O2，是一種可逆的，非選擇性的聯氨類單胺氧化酶抑制劑，能用於抗抑鬱藥[2]，由輝瑞公司開發，後因肝毒性問題撤回[3][4]。
參考文獻
- ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-16]. （原始內容存檔於2023-08-03） （巴西葡萄牙語）.
- ^ William Andrew Publishing. Pharmaceutical Manufacturing Encyclopedia 3rd. Elsevier. 1 December 2006: 2935–. ISBN 978-0-8155-1856-3.
- ^ Gad SC. Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. 26 April 2012: 138–. ISBN 978-1-4398-4567-7.
- ^ Shorter, Edward. Before Prozac: The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. 28 September 2008: 137–. ISBN 978-0-19-970933-5.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||